3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow Thyroid Dyshormonogenesis 2A: new trials by email Literature Review of Thyroid Dyshormonogenesis 2A trials Research Report on Thyroid Dyshormonogenesis 2A
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safinamide for Multiple System Atrophy (MSA) Safinamide Methanesulfonate, Safinamide Methanesulfonate matching placebo - Multiple System Atrophy | Phase 2 | Completed | Zambon SpA | 49 | 2019-10-29 | 2021-10-13 |
| AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients AZD3241, Placebo - Multiple System Atrophy, MSA | Phase 2 | Completed | AstraZeneca | 59 | 2015-04-27 | 2017-09-25 |
| Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins intravenous immunoglobulin (IVIg) - Multiple System Atrophy | Phase 2 | Completed | University of Massachusetts, Worcester | 9 | 2008-06-01 | 2017-02-23 |
Autonomic Nervous System Diseases (3) · Basal Ganglia Diseases (3) · Brain Diseases (3) · Central Nervous System Diseases (3) · Movement Disorders (3) · Nervous System Diseases (3) · Neurodegenerative Diseases (3) · Primary Dysautonomias (3) · Synucleinopathies (3)
AZD3241 (1) · Immunoglobulins, Intravenous (1) · safinamide (1)
AstraZeneca (1) · University of Massachusetts, Worcester (1) · Zambon SpA (1)
Italy (2) · United States (2) · Austria (1) · Finland (1) · France (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Charlotte Keywood, MD (1) · Peter Novak, MD, PhD (1)
2018 (1)